Table
3: Univariate
analysis of health characteristics factors affecting the development of diabetic
nephropathy complication.
|
Health characteristics |
ba |
Crude OR (95% CIb) |
P value |
|
BMI |
-0.21 |
0.80
(0.77,0.84) |
< 0.001 |
|
WC |
-0.07 |
0.92
(0.90,0.94) |
< 0.001 |
|
Duration of diabetes |
0.09 |
1.09
(1.05,1.14) |
< 0.001 |
|
Macrovascular
complications No Yes |
0 1.71 |
1 5.56
(2.02,15.31) |
- 0.001 |
|
Antidiabetic medications Metformin |
0 |
1 |
0.003 - |
|
Gliclazide |
1.00 |
2.72
(0.91,8.09) |
0.071 |
|
Mixtard insulin |
1.75 |
5.75 (1.24,26.62) |
0.025 |
|
Metformin + Gliclazide |
0.29 |
1.34
(0.66,2.71) |
0.411 |
|
Metformin + Mixtard
insulin |
0.49 |
1.63
(0.67,3.99) |
0.278 |
|
Gliclazide + Acarbose |
2.15 |
8.57
(1.08,68.12) |
0.042 |
|
Metformin + Gliclazide
+ Rosiglitazone |
0.44 |
0.63
(0.28,1.45) |
0.284 |
|
Metformin + Gliclazide
+ Acarbose |
0.34 |
1.40
(0.59,3.30) |
0.435 |
|
Metformin + Gliclazide
+ NPH insulin |
1.15 |
3.17
(1.19,8.40) |
0.020 |
|
Retinopathy No Yes |
0 0.55 |
1 1.74
(1.10,2.75) |
- 0.016 |
|
Neuropathy No Yes |
0 0.81 |
1 2.24
(1.47,3.44) |
- <
0.001 |
OR: Odds Ratio;
CI: Confidence Interval
aSimple logistic regression ( outcome as
nephropathy complication)
References category: macrovascular
complication: no, references category: antidiabetic
medication: metformin, references category retinopathy: no, references category
neuropathy: no